Royce & Associates LP Sells 485,914 Shares of Surgery Partners, Inc. (NASDAQ:SGRY)

Royce & Associates LP decreased its position in Surgery Partners, Inc. (NASDAQ:SGRY - Free Report) by 95.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 24,347 shares of the company's stock after selling 485,914 shares during the period. Royce & Associates LP's holdings in Surgery Partners were worth $515,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of SGRY. KBC Group NV grew its holdings in shares of Surgery Partners by 31.8% in the third quarter. KBC Group NV now owns 2,385 shares of the company's stock valued at $77,000 after acquiring an additional 576 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. grew its stake in Surgery Partners by 747.6% in the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,831 shares of the company's stock valued at $124,000 after purchasing an additional 3,379 shares during the period. MeadowBrook Investment Advisors LLC increased its position in shares of Surgery Partners by 16.6% during the 4th quarter. MeadowBrook Investment Advisors LLC now owns 10,280 shares of the company's stock valued at $218,000 after purchasing an additional 1,460 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Surgery Partners during the 4th quarter worth $245,000. Finally, AlphaCentric Advisors LLC purchased a new position in shares of Surgery Partners in the 4th quarter worth about $374,000.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on SGRY. Macquarie dropped their target price on shares of Surgery Partners from $34.00 to $33.00 and set an "outperform" rating on the stock in a research note on Tuesday, March 11th. Bank of America initiated coverage on Surgery Partners in a research note on Monday, December 16th. They issued a "buy" rating and a $30.00 price objective on the stock. JPMorgan Chase & Co. decreased their target price on Surgery Partners from $38.00 to $28.00 and set a "neutral" rating for the company in a research report on Tuesday, December 3rd. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $35.00 price target on shares of Surgery Partners in a research report on Tuesday. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat, Surgery Partners presently has an average rating of "Moderate Buy" and a consensus target price of $36.63.

Remove Ads

Insider Buying and Selling at Surgery Partners

In related news, CFO David T. Doherty sold 13,641 shares of Surgery Partners stock in a transaction on Friday, February 7th. The stock was sold at an average price of $25.61, for a total transaction of $349,346.01. Following the completion of the sale, the chief financial officer now owns 108,862 shares of the company's stock, valued at approximately $2,787,955.82. This trade represents a 11.14 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Marissa Brittenham sold 3,156 shares of the company's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $24.09, for a total value of $76,028.04. Following the completion of the transaction, the insider now owns 63,408 shares in the company, valued at $1,527,498.72. This represents a 4.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 106,622 shares of company stock valued at $2,717,860 in the last three months. Company insiders own 2.30% of the company's stock.

Surgery Partners Price Performance

SGRY traded down $0.17 during trading on Wednesday, reaching $24.02. 489,085 shares of the company were exchanged, compared to its average volume of 1,060,869. Surgery Partners, Inc. has a 12-month low of $19.50 and a 12-month high of $33.97. The company's 50-day moving average is $24.08 and its two-hundred day moving average is $25.65. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99. The company has a market cap of $3.07 billion, a price-to-earnings ratio of -50.04, a P/E/G ratio of 19.21 and a beta of 2.73.

Surgery Partners (NASDAQ:SGRY - Get Free Report) last released its quarterly earnings data on Monday, March 3rd. The company reported $0.39 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.01. The company had revenue of $864.40 million during the quarter, compared to analyst estimates of $828.09 million. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. Research analysts forecast that Surgery Partners, Inc. will post 0.67 earnings per share for the current fiscal year.

Surgery Partners Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.